7.21

4.22% -0.34

Replimune Group Inc (REPL)

Overview News Price History Option Chain Financials Discussions Forecast

Replimune Group Inc stock is traded at $7.21, with a volume of 9.75M. It is down -4.22% in the last 24 hours and down -22.16% over the past month. Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.

Previous Close:

$7.55

Open:

$6.93

24h Volume:

9.75M

Relative Volume:

1.45

Market Cap:

$557.34M

Revenue:

Net Income/Loss:

$-209.96M

P/E Ratio:

-2.2816

EPS:

-3.16

Net Cash Flow:

$-176.27M

1W Performance:

+133.27%

1M Performance:

-22.16%

6M Performance:

-48.27%

1Y Performance:

-27.69%

1-Day Range:

$6.67

$7.62

1-Week Range:

$3.02

$8.07

52-Week Range:

$2.68

$17.00

Replimune Group Inc Stock (REPL) Company Profile

Name

Replimune Group Inc

Sector

Healthcare (1167)

Industry

Biotechnology (653)

Phone

(781) 222-9600

Address

500 UNICORN PARK, WOBURN, MA

Employee

479

Twitter

@Replimune

Next Earnings Date

2025-02-11

Latest SEC Filings

REPL's Discussions on Twitter

Compare REPL with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
REPL Replimune Group Inc	7.23	291.78M	0	-209.96M	-176.27M	-3.16
VRTX Vertex Pharmaceuticals Inc	467.56	120.29B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	557.12	60.26B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	397.56	43.10B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	679.61	36.65B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	301.13	33.09B	3.81B	-644.79M	-669.77M	-6.24

Replimune Group Inc Stock (REPL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-30-25	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Jul-23-25	Downgrade	BMO Capital Markets	Outperform → Underperform
Jul-23-25	Downgrade	Barclays	Overweight → Equal Weight
Jul-23-25	Downgrade	H.C. Wainwright	Buy → Neutral
Jul-22-25	Downgrade	JP Morgan	Overweight → Neutral
Jul-22-25	Downgrade	Leerink Partners	Outperform → Market Perform
Jul-22-25	Downgrade	Piper Sandler	Overweight → Neutral
Jul-22-25	Downgrade	Wedbush	Outperform → Neutral
Jun-20-25	Initiated	Cantor Fitzgerald	Overweight
Aug-28-24	Initiated	ROTH MKM	Buy
Apr-17-23	Resumed	Piper Sandler	Overweight
Nov-19-21	Initiated	Piper Sandler	Overweight
Oct-15-21	Resumed	BTIG Research	Buy
Nov-17-20	Initiated	BTIG Research	Buy
Nov-02-20	Initiated	Jefferies	Buy
Oct-15-20	Upgrade	H.C. Wainwright	Neutral → Buy
Jul-01-20	Downgrade	H.C. Wainwright	Buy → Neutral
May-05-20	Initiated	Barclays	Overweight
Sep-04-19	Initiated	ROTH Capital	Buy
Jul-23-19	Initiated	Chardan Capital Markets	Buy
Jul-12-19	Upgrade	JP Morgan	Neutral → Overweight
Jul-08-19	Initiated	H.C. Wainwright	Buy
Apr-25-19	Initiated	Wedbush	Outperform
Jan-23-19	Downgrade	JP Morgan	Overweight → Neutral
Aug-14-18	Initiated	JP Morgan	Overweight
Aug-14-18	Initiated	Leerink Partners	Outperform

View All

Replimune Group Inc Stock (REPL) Latest News

09:08 AM

Replimune (REPL) Faces Securities Class Action Following Stock's Collapse Amid FDA's Rejection of Melanoma DrugHagens Berman - PR Newswire

09:08 AM

08:45 AM

The Gross Law Firm Reminds Replimune Group, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 22, 2025REPL - Morningstar

08:45 AM

08:02 AM

Why Is Replimune Stock (NASDAQ:REPL) Exploding? - TipRanks

08:02 AM

12:44 PM

Replimune's Stock Volatility: Navigating Biotech Uncertainty and Immuno-Oncology's Long-Term Promise - AInvest

12:44 PM

12:21 PM

How to escape a deep drawdown in Replimune Group Inc.Free Beginner Friendly Stock Selection Guide - Newser

12:21 PM

Jul 30, 2025

Replimune Stock Catches Retail Fire As Analyst Says FDA Shakeup Removes 'Major Obstacle' For Skin Cancer Drug's Potential Approval - Stocktwits

Jul 30, 2025

Investor Alert: Deadline Approaching to Join Replimune Group, Inc. (REPL) Class ActionContact Levi & Korsinsky - ACCESS Newswire

Jul 30, 2025

REPL Class Action Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Securities Fraud Class Action Involving Replimune Group, Inc. - Morningstar

Jul 30, 2025

Order flow analysis tools used on Replimune Group Inc.Chart-Based Entry Confirmation for Beginners - Newser

Jul 30, 2025

Jul 29, 2025

REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Lawsuit First Filed by The Rosen Law Firm - The Malaysian Reserve

Jul 29, 2025

Shareholders who lost money on Replimune Group, Inc. - GlobeNewswire

Jul 29, 2025

Shareholders who lost money on Replimune Group, Inc. (NASDAQ: REPL) Should Contact Wolf Haldenstein Immediately as Lead Plaintiff Deadline is September 22nd - GlobeNewswire Inc.

Jul 29, 2025

Replimune Faces Investor Lawsuit Over IGNYTE Trial - TipRanks

Jul 29, 2025

Levi & Korsinsky Notifies Replimune Group, Inc. (REPL) InvestorsLead Plaintiff Deadline on September 22, 2025 - ACCESS Newswire

Jul 29, 2025

Replimune Group (REPL.O) Sees Sharp Intraday Surge — But Why? - AInvest

Jul 29, 2025

Replimune Faces Market Turbulence: FDA Rejection Leads to Legal Trouble - StocksToTrade

Jul 29, 2025

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune - Morningstar

Jul 29, 2025

Combining machine learning predictions for Replimune Group Inc.AI Entry Timing Prediction for Swing Traders - Newser

Jul 29, 2025

Market reaction to Replimune Group Inc.’s recent newsFree Stock Market Watch With Alerts - Newser

Jul 29, 2025

How to track smart money flows in Replimune Group Inc.Trend Reversal Probability Forecast Update - Newser

Jul 29, 2025

Jul 28, 2025

Investors in Replimune Group, Inc. (REPL) Warned of Potential Securities FraudContact Levi & Korsinsky Today - ACCESS Newswire

Jul 28, 2025

Replimune’s SWOT analysis: biotech stock faces FDA setback, industry remains positive - Investing.com

Jul 28, 2025

SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire

Jul 28, 2025

REPL LAWSUIT: Replimune Group, Inc. Sued for Fraud after - GlobeNewswire

Jul 28, 2025

REPL LAWSUIT NOTICE: Replimune Group, Inc. Investors are Notified of the Pending Securities Fraud Class ActionContact BFA Law before the September 22 Deadline - ACCESS Newswire

Jul 28, 2025

REPL INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Replimune Group, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - PR Newswire

Jul 28, 2025

Ongoing Investigation: Replimune Group, Inc. (REPL) May Have Misled ShareholdersLevi & Korsinsky Investigates - ACCESS Newswire

Jul 28, 2025

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines – REPL - FinancialContent

Jul 28, 2025